1. Home
  2. PRSO vs HCWB Comparison

PRSO vs HCWB Comparison

Compare PRSO & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.76

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

HCWB

HCW Biologics Inc.

HOLD

Current Price

$3.30

Market Cap

14.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
HCWB
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
14.8M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
PRSO
HCWB
Price
$0.76
$3.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$35.00
AVG Volume (30 Days)
403.7K
459.2K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
N/A
EPS
N/A
0.37
Revenue
$14,573,000.00
$4,099,750.00
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
$10.35
Revenue Growth
5.99
N/A
52 Week Low
$0.73
$0.25
52 Week High
$2.37
$7.35

Technical Indicators

Market Signals
Indicator
PRSO
HCWB
Relative Strength Index (RSI) 41.56 51.53
Support Level N/A $0.37
Resistance Level $0.94 $3.89
Average True Range (ATR) 0.05 0.39
MACD 0.00 -0.13
Stochastic Oscillator 20.49 8.94

Price Performance

Historical Comparison
PRSO
HCWB

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: